HHS awards Summit Therapeutics $32 to develop new C diff antibiotic

Listen
Text
  • Small
  • Medium
  • Large

HHS is partnering with Oxford, England-based Summit Therapeutics to develop a new antibiotic to treat Clostridium difficile.

Through the partnership, HHS' Biomedical Advanced Research and Development Authority will give Summit $32 million over two years to conduct two Phase 3 clinical trials of its experimental drug Ridinilazole.

The drugmaker is also eligible to receive a three-year extension on the contract with total potential funding of $62 million.

To learn more about C diff, click here.

More articles on infection control: 
Study suggests possible link between repeat flu vaccination and miscarriage 
Study: Antibiotic use may boost superbug spread in nursing homes 
Pet store puppies sicken 39 people in multistate bacterial outbreak

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars